Our News

  • ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

    28 Jul 2020. ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the Belgian Federal Government via SFPI-FPIM, V-Bio Ventures and several Belgian family offices.

  • Syndesi Therapeutics announces the expansion of its management team with the appointment of Torsten Madsen, MD, PhD as Chief Medical Officer.

    19 Dec 2019. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced Torsten Madsen MD, PhD has joined its management team as Chief Medical Officer.

  • Locana Expands Leadership Team with Appointment of former Casebia CEO as Chief Executive Officer

    10 Dec 2019. Locana, Inc., a leading RNA-targeting gene therapy company, today announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned transition of the company's director and recent CEO, Jeffrey M. Ostrove, Ph.D., to continue service as director.

  • Sarepta and StrideBio Announce Multi-target Collaboration to Advance Novel Gene Therapies

    14 Nov 2019. Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system (CNS) and neuromuscular targets.

  • Locana appoints Kathie Bishop, Ph.D., as Chief Scientific Officer

    04 Sep 2019. Locana, a leading RNA-targeting gene therapy company, today announced the appointment of Kathie M. Bishop, Ph.D. as chief scientific officer. Dr. Bishop is a neuroscientist and drug development leader with 20 years of pharmaceutical industry experience covering a broad spectrum of therapeutic areas.

  • Ally secured seed finance from ARCH Venture Partners, Alta Partners and UCB Ventures to advance its novel gene therapy platform.

    31 July 2019. Ally secured seed finance from ARCH Venture Partners, Alta Partners and UCB Ventures to advance its novel gene therapy platform. 

  • Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies

    22 May 2019. Locana, Inc., a leading RNA-targeting gene therapy company, announced today the close of a $55 million Series A financing led by ARCH Venture Partners with participation from Temasek and Lightstone Ventures, all existing investors. New investors include UCB Ventures and GV (formerly Google Ventures).

  • Rinri Therapeutics secures £1.4 million seed funding to advance its novel regenerative cell therapy to treat sensorineural hearing loss

    20 May 2019. Rinri Therapeutics, a biotechnology company developing a novel cell- based therapy to restore hearing, announced today that it successfully secured £1.4 million in seed funding. The financing, which was co-led by Boehringer Ingelheim Venture Fund and UCB Ventures and joined by BioCity, will support the ongoing growth of the company.

  • Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator in development for treatment of cognitive impairment

    08 May 2019. Syndesi Therapeutics SA, a biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment, today announced that its lead molecule, SDI-118, has entered into Phase I clinical development.

  • StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases

    28 March 2019. Multi-target deal will utilize StrideBio's platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich's Ataxia.

  • Syndesi Therapeutics awarded non-dilutive funding of up to €3.2M for development of its lead program, SDI-118, aimed at treating cognitive impairment

    20 March 2019. Developing novel SV2A modulators for cognitive impairment, today announced it has been granted up to EUR 3.2 M in non-dilutive funding from the Walloon Region.

  • UCB Ventures Appoints Alicia Irurzun-Lafitte as Partner

    06 March 2019. UCB Ventures, the corporate venture arm of UCB Pharma, today announced that Alicia Irurzun-Lafitte will join UCB Ventures as Partner in Boston. Alicia brings 10 years of deal making experience, spanning business development transactions to early stage investments in biotech.

  • CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

    19 February 2019. CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced that …

  • StrideBio Appoints Sapan Shah, Ph.D. as Chief Executive Officer

    03 January 2019. StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, announced today that the Board of Directors has appointed Sapan Shah, Ph.D. as Chief Executive Officer and a member of the company's board.

  • Read the interview with Erica Whittaker in BioCentury

    22 June 2018. Description: UCB Ventures' recent investment in Durham, N.C.-based gene therapy play StrideBio Inc. marks the next phase in how the strategic investor plans to deploy its €150 million ($174 million) fund.

  • UCB Ventures makes its first direct investment

    13 June 2018. UCB Ventures announces its first direct investment in the oversubscribed $15.7 million Series A Financing Round for StrideBio, Inc., …

  • UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics to develop novel therapeutics for cognitive disorders

    01 February 2018. We have recently announced the creation of Syndesi Therapeutic to further develop the research …